CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027 [Seeking Alpha]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Seeking Alpha
Incremental buying is attractive now for patient CRSP investors, with major upside expected as revenue scales and normalized EPS turns positive, likely post-2027. The 60/40 global profit split with Vertex offers operating leverage, positioning CRSP for free cash flow as adoption and execution improve. CRSP stock is rated Buy, with the most reliable alpha expected when long-term investing in late 2027 and 2028, as fundamentals catch up to clinical progress. Comstock/Stockbyte via Getty Images CRISPR Therapeutics AG ( CRSP ), which has traded approximately flat since my last analysis of the company, has entered 2026 with strong proof of concept. Fiscal 2025 has demonstrated early-stage commercial traction, but the company's financials undoubtedly This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this artic
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Should You Buy Shares of CRISPR Therapeutics in February? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (NASDAQ:CRSP) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Is CRISPR Therapeutics' (CRSP) Casgevy Momentum Enough to Offset Steep 2025 Revenue Declines? [Yahoo! Finance]Yahoo! Finance
- Crispr Therapeutics price target raised to $82 from $80 at Needham [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/12/26 - Miss
CRSP
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/12/26 - Form 10-K
- 2/12/26 - Form 8-K
- CRSP's page on the SEC website